Please use this identifier to cite or link to this item:
Title: Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
Authors: Lim L.Y.
Miao H.
Lim J.S.J.
Lee S.C.
Bhoo-Pathy N.
Yip C.H.
Taib N.A.B.M.
Chan P.
Tan E.Y.
Lim S.H.
Lim G.H.
Woo E.
Tan Y.S.
Lee J.A.
Wong M.
Tan P.H.
Ong K.W.
Wong F.Y.
Yap Y.S.
Hartman M. 
Keywords: Breast cancer
clinicopathologic predictors
neoadjuvant chemotherapy
pathologic complete response
Issue Date: 1-Jan-2017
Publisher: Blackwell Publishing Ltd
Citation: Lim L.Y., Miao H., Lim J.S.J., Lee S.C., Bhoo-Pathy N., Yip C.H., Taib N.A.B.M., Chan P., Tan E.Y., Lim S.H., Lim G.H., Woo E., Tan Y.S., Lee J.A., Wong M., Tan P.H., Ong K.W., Wong F.Y., Yap Y.S., Hartman M. (2017-01-01). Outcome after neoadjuvant chemotherapy in Asian breast cancer patients. Cancer Medicine 6 (1) : 173-185. ScholarBank@NUS Repository.
Abstract: We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. pCR following neoadjuvant chemotherapy was defined as 1) no residual invasive tumor cells in the breast (ypT0/is) and 2) no residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is ypN0). Association between pCR and clinicopathologic characteristics and treatment were evaluated using chi-square test and multivariable logistic regression. Kaplan朚eier analysis and log-rank test, stratified by other prognostic factors, were conducted to compare overall survival between patients who achieved pCR and patients who did not. Overall, 4.4% of nonmetastatic patients received neoadjuvant chemotherapy. The median age of preoperatively treated patients was 50爕ears. pCR rates were 18.1% (pCR ypT0/is) and 14.4% (pCR ypT0/is ypN0), respectively. pCR rate was the highest among women who had higher grade, smaller size, estrogen receptor negative, human epidermal growth factor receptor 2-positive disease or receiving taxane-based neoadjuvant chemotherapy. Patients who achieved pCR had better overall survival than those who did not. In subgroup analysis, the survival advantage was only significant among women with estrogen receptor-negative tumors. Patients with poor prognostic profile are more likely to achieve pCR and particularly when receiving taxane-containing chemotherapy. pCR is a significant prognostic factor for overall survival especially in estrogen receptor-negative breast cancers. � 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Source Title: Cancer Medicine
ISSN: 20457634
DOI: 10.1002/cam4.985
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
cam4.985.pdf237.89 kBAdobe PDF




checked on Sep 24, 2018

Page view(s)

checked on Sep 20, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.